The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease.
The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease.
复制标题
DOI：
10.3390/biomedicines10071492
复制
发表时间：
2022-06-24
期刊：
影响因子：
4.7
通讯作者：
中科院分区：
文献类型：
--
作者：
炎症性肠病（IBD）是一种影响患者胃肠道的慢性炎症，其诊断和预后具有挑战性，因为大多数临床症状并非IBD所特有，并且通常见于其他炎症性疾病，如肠道感染、药物诱导的结肠炎和单基因疾病。到目前为止，还没有监测IBD的金标准测试。内窥镜检查和成像是必不可少的诊断工具，可提供有关疾病状态、位置和严重程度的信息。然而，内窥镜检查的侵入性和高成本使其不适合经常监测IBD患者的疾病活动，即使有可能用成像代替内窥镜检查，高成本仍然是一个问题。血液或粪便的实验室检测具有非侵入性、快速、成本效益高和可扩展的优点。虽然单独实验室检测的特异性和准确性需要提高，但它越来越多地用于监测疾病活动或与内窥镜检查和/或成像相结合诊断疑似IBD病例。文献调查表明缺乏IBD检测生物标志物的总结。本文介绍了目前IBD实验室检测中具有临床意义的非侵入性生物标志物，并讨论了IBD生物标志物研究的趋势和挑战。
Diagnosis and prognosis of inflammatory bowel disease (IBD)—a chronic inflammation that affects the gastrointestinal tract of patients—are challenging, as most clinical symptoms are not specific to IBD, and are often seen in other inflammatory diseases, such as intestinal infections, drug-induced colitis, and monogenic diseases. To date, there is no gold-standard test for monitoring IBD. Endoscopy and imaging are essential diagnostic tools that provide information about the disease’s state, location, and severity. However, the invasive nature and high cost of endoscopy make it unsuitable for frequent monitoring of disease activity in IBD patients, and even when it is possible to replace endoscopy with imaging, high cost remains a concern. Laboratory testing of blood or feces has the advantage of being non-invasive, rapid, cost-effective, and standardizable. Although the specificity and accuracy of laboratory testing alone need to be improved, it is increasingly used to monitor disease activity or to diagnose suspected IBD cases in combination with endoscopy and/or imaging. The literature survey indicates a dearth of summarization of biomarkers for IBD testing. This review introduces currently available non-invasive biomarkers of clinical importance in laboratory testing for IBD, and discusses the trends and challenges in the IBD biomarker studies.
登录
查看更多内容
影响因子：
3.7
作者：
Duttagupta R;DiRienzo S;Jiang R;Bowers J;Gollub J;Kao J;Kearney K;Rudolph D;Dawany NB;Showe MK;Stamato T;Getts RC;Jones KW
通讯作者：
Jones KW
影响因子：
3.6
作者：
Bharadwaj S;Narula N;Tandon P;Yaghoobi M
通讯作者：
Yaghoobi M
影响因子：
4.9
作者：
Cooke, James;Zhang, Hu;Parkes, Miles
通讯作者：
Parkes, Miles
影响因子：
28.2
作者：
Ellis MJ;Gillette M;Carr SA;Paulovich AG;Smith RD;Rodland KK;Townsend RR;Kinsinger C;Mesri M;Rodriguez H;Liebler DC;Clinical Proteomic Tumor Analysis Consortium (CPTAC)
通讯作者：
Clinical Proteomic Tumor Analysis Consortium (CPTAC)
影响因子：
2.9
作者：
Burakoff, Robert;Hande, Scott;Liew, Choong-Chin
通讯作者：
Liew, Choong-Chin